We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Dalton Medicinal Chemistry Partners Signs Agreement with Boehringer Ingelheim

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces the signing of a Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd.

Dalton Medicinal Chemistry Partners will utilise their medicinal chemistry expertise to design and synthesise novel compounds against a number of antiviral targets selected by Boehringer Ingelheim (Canada) Ltd.

Peter Pekos, President of Dalton Pharma Services, said: "We are pleased to enter this exciting partnership with Boehringer Ingelheim (Canada) Ltd by bringing the added value of our medicinal chemistry capabilities and expertise to their antiviral research projects."